Alpha1 Antitrypsin Deficiency - Institute for Respiratory Health

Alpha1 Antitrypsin Deficiency

Study Outline

This study is:

  • Approximately 3 years
  • Phase III
  • Safety and Efficacy of two dose regimens of the study drug
  • Weekly infusions

To find out if this trial is suitable for you please register below or contact our Clinical Trials Team at admin@resphealth.uwa.edu.au or phone 6151 0888.

Eligibility & Requirements

  • 18- 70 years old
  • Diagnosis of Alpha 1 Antitrypsin Deficiency with evidence of emphysema
  • No flare up of the chest in the last 5 weeks prior to the first visit
  • No cancer in last 5 years

What's Involved

  • You will be required to come once a week for 3 years for treatment including health checks to Sir Charles Gairdner Hospital.
  • CT scans of your lungs will be required on 5 occasions throughout the trial.
Register your interest in this Clinical Trial
  • This field is for validation purposes and should be left unchanged.
Current Clinical Trials